TROCEPT-01 (ATTR-01)
Solid Cancers
Phase 1Active
Key Facts
About Accession Therapeutics
Accession Therapeutics is an emerging private biotech company pioneering a differentiated approach in immuno-oncology with its Trocept platform, a stealth virus technology engineered for tumor-specific entry. The company has advanced its lead candidate, TROCEPT-01 (ATTR-01), into a Phase 1 trial (ATTEST) for solid cancers and is building a broader pipeline. Backed by significant recent funding and led by an experienced team, including immuno-oncology pioneer Bent Jakobsen, Accession is positioning itself to address the limitations of current immunotherapies.
View full company profileTherapeutic Areas
Other Solid Cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| Two GATE™ (Undisclosed Targets) | Revitope Oncology | Preclinical |
| VicOryx | Oryx Translational Medicine | Phase 1/2 |
| MicOryx | Oryx Translational Medicine | Phase 1/2 |
| Undisclosed TCR Program(s) | Captain T Cell | Pre-clinical |